ExoNeuglia Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A1

  • Investors
  • 3

ExoNeuglia General Information

Description

Developer of nervous system-related stem cell drugs intended to treat demyelinating diseases. The company uses induced pluripotent stem cell technology to develop medicines to treat demyelinating diseases, helping patients with loss of myelin in the nervous system and conditions such as spinal cord injury, multiple sclerosis, Guillain-Barré syndrome, neuromyelitis optica, etc.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 403, 4th Floor, Building M2, 2.5 Industrial Park, No. 88 Dongchang Road
  • Suzhou Industrial Park, Suzhou Area, China Pilot Free Trade Zone
  • Suzhou, Jiangsu 215000
  • China
+86 189
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 403, 4th Floor, Building M2, 2.5 Industrial Park, No. 88 Dongchang Road
  • Suzhou Industrial Park, Suzhou Area, China Pilot Free Trade Zone
  • Suzhou, Jiangsu 215000
  • China
+86 189

ExoNeuglia Timeline

2023202420252026
Date FoundedFinancing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ExoNeuglia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A1) 06-Aug-2025 Completed Generating Revenue
2. Early Stage VC (Series A) 18-Jul-2024 Completed Generating Revenue
1. Seed Round 08-Dec-2022 $7.02M $7.02M Completed Startup
To view ExoNeuglia’s complete valuation and funding history, request access »

ExoNeuglia Patents

ExoNeuglia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025107757-A1 In vitro preparation method for medial ganglionic eminence progenitor cells and gaba interneurons Inactive 20-Nov-2023
WO-2025008000-A1 Culture medium and method for efficiently inducing muscle stem cells Inactive 05-Jul-2023
EP-4741496-A1 Method for reprogramming human somatic cells into induced pluripotent stem cells Pending 04-Jul-2023
EP-4741496-A4 Method for reprogramming human somatic cells into induced pluripotent stem cells Pending 04-Jul-2023
US-20260132384-A1 Method for reprogramming human somatic cells into induced pluripotent stem cells Pending 04-Jul-2023 C12N5/0696
To view ExoNeuglia’s complete patent history, request access »

ExoNeuglia Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ascentage Pharma Corporation Minority
Grains Valley Venture Capital Venture Capital Minority
Redhill Capital Growth/Expansion Minority
To view ExoNeuglia’s complete investors history, request access »

ExoNeuglia FAQs

  • When was ExoNeuglia founded?

    ExoNeuglia was founded in 2022.

  • Where is ExoNeuglia headquartered?

    ExoNeuglia is headquartered in Suzhou, China.

  • What industry is ExoNeuglia in?

    ExoNeuglia’s primary industry is Drug Discovery.

  • Is ExoNeuglia a private or public company?

    ExoNeuglia is a Private company.

  • What is ExoNeuglia’s current revenue?

    The current revenue for ExoNeuglia is .

  • How much funding has ExoNeuglia raised over time?

    ExoNeuglia has raised $7.02M.

  • Who are ExoNeuglia’s investors?

    Ascentage Pharma, Grains Valley Venture Capital, and Redhill Capital have invested in ExoNeuglia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process